- Division of Translational and Clinical Sciences – DTCS
- Review Branch:
- Respiratory, Cardiac, and Circulatory Sciences – RCCS
- Study Section:
- Therapeutic Development and Preclinical Studies – TDPS
Dr. Richard Schneiderman received his Ph.D. in immunology from The University of Illinois, Chicago, where he studied cellular and molecular mechanisms regulating immunoglobulin A expression and function. He completed postdoctoral training in retroviral biology and gene therapy initially at Genetic Therapy Inc. in Gaithersburg, MD. Dr. Schneiderman then served in the Laboratory of Cell Biology at the NIH National Institute of Mental Health, investigating vector biology, receptor interaction and host restriction. He then moved to Baxter Healthcare Corporation, where he was a Principal Scientist investigating a number of gene and cell therapy approaches for hemophilia and diabetes. Before coming to CSR, Dr. Schneiderman was a Principal Scientist at Boehringer Ingelheim Pharmaceuticals and Acorda Therapeutics investigating therapeutic treatments for cardiovascular diseases including atherosclerosis, heart failure, and hypertension.